Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- LDP Subcommittee Holds Hearing on Unification of Dispensing Fees
July 25, 2011
- “Biosimilars Era”Coming to Japan: Mr Sawai of JGA
July 25, 2011
- JPA to Collect ADR Avoidance Case Reports from Pharmacies
July 25, 2011
- Merck Serono to Enter 2nd High Growth Stage after Stable Growth in 2011-2012: President Smith
July 25, 2011
- No Major Obstacle to Japan's Participation in PIC/S: Chairman Graberg
July 25, 2011
- Teva Obtains All Shares from Taiyo Pharm. for ¥74 Bil.
July 25, 2011
- APEX to Build Up Nationwide Network
July 25, 2011
- Drug Production in March Down as Much as 65% in 3 Quake-hit Prefectures: Korosho
July 25, 2011
- Rivaroxaban Approved for Prevention of DVT in the US
July 25, 2011
- HPB Issues Notification Aimed at Increasing Efficiency of Clinical Trials
July 25, 2011
- J-CKDI Predicts Dialysis Patients to Decrease after Peak in 2017
July 25, 2011
- Antiepileptic Agent Rufinamide Approved in Canada: Eisai
July 18, 2011
- Over 70% of Women Aware of HPV Vaccine: Survey
July 18, 2011
- FDA Committee Recommends Withdrawal of Breast Cancer Indication from Avastin
July 18, 2011
- Bristol-Myers to Create Friendlier Work Environment for Women
July 18, 2011
- Council on Unapproved Drugs to Revise Assessment Criteria
July 18, 2011
- STATISTICS
July 18, 2011
- Sales of Ethical Drugs Up 7.5% in May: Crecon & Research Consulting
July 18, 2011
- Bayer Aiming for Top-10 Spot in Global Ethical Drug Market by 2015
July 18, 2011
- JACDS, JPA to Cooperate Regarding nternet Drug Sales, Unification of Basic Dispensing Fees
July 18, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…